Summary: Ferrous sulphate administered together with tetracycline and three of its derivatives-oxytetracycline, methacycline, and doxycycline-was found seriously to impair the absorption of these antibiotics. Thus even small doses of iron taken simultaneously should be avoided during tetracycline treatment.
Five patients (Cases 1, 3, 4, 5, and 9) have died since the study was begun. One death (Case 4) resulted from fibrosing 160-,140. 
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alveolitis due to "busulphan lung." The other four patients died after a myeloblastic crisis, and in two of these no histological abnormality of the lung was found at necropsy. In the other two cases permission for necropsy was refused, but antemortem chest radiographs and physiological studies were normal. Two of these patients had received a much larger dose of busulphan than the patient who developed fibrosing alveolitis (Table VII) , and a further six patients who are alive and well also received a dose in excess of 1,000 mg. (see Table II ). The lack of any relationship between busulphan dosage and transfer factor is illustrated in the Chart. Hence the development of fibrosing alveolitis may be related to the genetic or immunological constitution of the patient rather than to the dose or duration of busulphan therapy.
The preliminary results of this study suggest that lung damage, detectable during life, is a relatively uncommon complication of busulphan treatment, occurring in only 1 out of 23 patients closely studied over an average period of nearly two years.
We 
Results
After 500 mg. of tetracycline a maximal serum concentration of 2.9 jug./ml. was reached in three hours (Fig. 1) and six hours, the average reduction being 80-85% (Fig. 3) (Greenberger et al., 1967) .
In I Introduction The present study was undertaken to investigate the recovery of adrenocortical function during very slow withdrawal of corticosteroids in a homogeneous population of patients who had been on this therapy for a number of years. Furthermore, we aimed to ascertain whether the very low dosages of prednisone given during the last stages of such a treatment were therapeutically active.
The 43 subjects who participated were part of a large group of patients suffering from pulmonary sarcoidosis who had been treated with prednisone for at least two years according to a uniform schedule (shown in Table I ). Besides determining the plasma fluorogenic corticosteroids, as usually undertaken in similar investigations, we measured the cortisol production rate by isotope dilution, in order to obtain the most reliable quantitative assessment of adrenocortical function. Ditmars, 1968) .
Of the patients studied 22 were men aged 25-63 and 21 were women aged 27-63. Twenty-seven were in hospital for six days. On the second day the cortisol production rate was determined; plasma fluorogenic corticosteroids were measured at 8.30 a.m. and 4.30 p.m. on days 3 and 4. On day 5 the patients received an intravenous infusion of 0.25 mg. of tetracosactrin (Synacthen) in 500 ml. of saline during eight hours. On the same day the cortisol production rate was again determined. Plasma fluorogenic corticosteroids were measured at the beginning and at the end of the infusion. Prednisone treatment was continued during all tests. Furthermore, 29 patients aged 20-61 with pulmonary sarcoidosis were investigated before prednisone treatment was started-in six the whole series of tests were done and in 23 the cortisol production rate only. For comparison the cortisol production rate was determined in 23 normal volunteer subjects (staff 2-5 mg.12 days
